Jointown Pharmaceutical Group (600998) Q3 2026 earnings summary

Executive summary

• Q3 revenue rose 10.32% YoY to RMB 42.17bn; adjusted attributable net profit rose 9.75% YoY and 29.45% QoQ to RMB 568.6m.

• 9M revenue grew 8.48% to RMB 129.45bn and adjusted attributable net profit increased 5.52% to RMB 1.551bn, driven by growth across core businesses.

• 9M reported attributable net profit declined 14.85%, primarily reflecting lower non-recurring gains than in the prior-year period.

Financial highlights

• Q3 revenue was RMB 42.166bn, up 10.32% YoY; attributable net profit was RMB 481.6m, down 9.11%, while adjusted attributable net profit was RMB 568.6m, up 9.75%.

• 9M revenue reached RMB 129.445bn, up 8.48%; total profit was RMB 2.297bn, down 14.87%, and attributable net profit was RMB 1.682bn, down 14.85%.

• 9M operating cash flow was negative RMB 2.019bn, improving 12.83% YoY; Q3 operating cash flow was positive RMB 761m.

Outlook and guidance

• Full-year operating cash flow is expected to be positive and aligned with operating performance; increased receivables collection is planned for Q4.